Zolpidem use and risk of suicide: A systematic review and meta-analysis
| Autoři | |
|---|---|
| Rok publikování | 2022 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Psychiatry Research |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/pii/S0165178122003717 |
| Doi | http://dx.doi.org/10.1016/j.psychres.2022.114777 |
| Klíčová slova | Death; Epidemiology; Insomnia; Systematic review; Meta-analysis; Suicide; Zolpidem |
| Popis | Introduction Zolpidem is one of the most commonly prescribed nonbenzodiazepine hypnotic drugs for insomnia. Published epidemiological studies linked zolpidem with the risk of suicide. However, to date, no meta-analysis investigated this association. Hence, we systematically reviewed and meta-analysed the current evidence from real-world studies reporting the risk of suicide with the use of zolpidem. Methods Medline (Ovid), Embase (Ovid), and PsycINFO databases were searched from inception till June 2021 for real-world evidence studies reporting the risk of suicide with the use of zolpidem. The quality assessment of included studies was assessed using the New-Castle Ottawa Scale (NOS). Random-effect meta-analysis was performed using a generic inverse variance method. Results This meta-analysis was based on four studies with 344,753 participants, of which 42,279 were zolpidem users. The methodological quality of all the included studies was of high quality. A significantly increased risk of suicide or suicide attempt was found in zolpidem users compared to non-users, with a pooled relative risk of 1.88 (95% CI: 1.54 – 2.30). Furthermore, an increased risk of suicidal death was observed in zolpidem users compared to non-users, with a pooled relative risk of 1.82 (95% CI: 1.43 – 2.30). Dose-response analysis also revealed a significantly increased risk of suicide in patients receiving ? 180cDDD (cumulative defined daily doses) of zolpidem (124 times), followed by 90–179cDDD (113 times) and <90cDDD (93 times) of zolpidem compared to non-users. Conclusion In conclusion, zolpidem use was associated with an increased risk of suicide or suicide attempt and suicidal death. Therefore, careful prescribing practices must be followed by considering the risk-benefit profile. |
| Související projekty: |